ArticleSchizophrenia research. Cognition2026
Cognitive decline in psychotic disorders: A longitudinal matched case-control study.
Article in Schizophrenia research. Cognition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with psychotic disorders often exhibit premorbid cognitive deficits and future cognitive changes following the onset of illness. This study examined cognitive trajectories in schizophrenia (SCZ), schizoaffective disorder (SZA) and bipolar disorder (BD) compared with healthy matched controls. Method: Cases included individuals with SCZ (n = 24), SZA (n = 15), or BD (n = 11), and 50 controls matched for age, sex, and socioeconomic status (SES). Participants underwent IQ testing at age 17 as part of mandatory military screening (T1); the same tests were administered after illness onset (T2). Results: Participants were assessed approximately 10 years after T1 (SD = 2.6). Cases with SCZ had a non-significant 4-point lower IQ than controls at T1. At T2, SCZ cases showed a 4-point IQ decline, whereas controls demonstrated a 5-point increase, resulting in a significant time × group interaction (F(1, 46) = 12.30, Conclusion: SCZ showed cognitive decline relative to controls over time, whereas SZA and BD demonstrated less pronounced cognitive changes. These findings are consistent with both neurodevelopmental and neurodegenerative models of psychotic illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.